Cellebrite Fourth Quarter 2025 Earnings Call - Guides 18%-19% ARR Growth in 2026 as SaaS, Corellium and Drone Forensics Drive Reacceleration

Speaker 8: Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star 0, and a member per team will be happy to help you. Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star 0, and a member per team will be happy to help you. Please stand by. Your meeting is about to begin. Welcome to the Cellebrite fourth quarter and full year 2025 financial results conference call. At this time, all participants have been placed on a listen-only mode, and the floor will be open for your questions following the presentation. If you would like to ask a question at that time, please press star 1 on your telephone keypad.

If at any point your question has been answered, you may remove yourself from the queue by pressing star 2 so others can hear your questions clearly. We ask that you pick up your handset for best sound quality. Lastly, if you should require operator assistance, please press star 0. I would now like to turn the call over to your first speaker today, Mr. Andrew Kramer. Mr. Kramer, the floor is yours.

Andrew Kramer, Investor Relations, Cellebrite: Thank you very much, operator, and welcome everybody to Cellebrite’s fourth quarter and full year 2025 financial results conference call. I’m joined today in Israel by our primary speakers, Tom Hogan, Cellebrite’s CEO, and David Barter, Cellebrite’s CFO. Marcus Jewell, our CRO, is also participating. This call is being recorded, and a replay of the recording will be made available on our website shortly after the call. We’ll also add a transcript. Please note a copy of today’s press release and financial statements, including GAAP and non-GAAP reconciliations, is available on the investor relations website at investors.cellebrite.com. In addition to the press release, we post a separate investor presentation that provides an overview of the business and our recent financial performance. I’d also like to remind everybody that the slide in your webcast viewer is a placeholder only. There are no actual slides to accompany our prepared remarks.

We also publish supplemental historical financial information for each quarter of 2025 and 2024, along with full year 2023 and 2022, on our investor relations website. Additionally, unless stated otherwise, our discussion of our fourth quarter and year-end 2025 financial metrics, as well as the financial metrics provided in our outlook, will be done on a non-GAAP basis only, and all historical comparisons are with the comparable periods of 2024. I’d like to remind you that today’s discussion will contain forward-looking statements, including but not limited to, the company’s business operations and financial performance. All forward-looking statements are subject to risks and uncertainties and other factors that could cause matters expressed or implied by those forward-looking statements not to occur. They could also cause the actual results to differ materially from the historical results and/or from forecasts.

Some of these forward-looking statements are discussed under the heading Risk Factors and elsewhere in the company’s annual report on Form 20-F filed with the SEC on March 18, 2025. The company does not undertake to update any forward-looking statements to reflect future events or circumstances. With that said, I’ll now turn the call over to Tom.

Tom Hogan, CEO, Cellebrite: Thanks, Andy. I’ll just jump right in. We closed 2025 with a solid fourth quarter that capped a year marked by meaningful strategic progress. We cemented our insights offering as the gold standard in digital forensics, drove strong adoption of our SaaS and cloud-based offerings, extended our integrated AI functionality, completed our first material acquisition, and added important talent across the company. We grew ARR by 21% in 2025, which factored the combination of a 4-point headwind from our U.S. federal unit’s actual performance versus our original plan and a nearly 4-point tailwind associated with the close of Corellium. Overall, our ARR growth reflects expansion across all of our major geographies and our flagship offerings. We outperformed relative to guidance on both our fourth quarter revenue and our Adjusted EBITDA.

Our growth and ongoing spend discipline delivered strong free cash flow of $160 million in 2025 and a 34% free cash flow margin. I’d like to quickly share some of our fourth quarter highlights and accomplishments that position us for accelerated growth in 2026. First, we’ve now converted 55% of our installed digital forensics base to Inseyets, exceeding our 50% target and reinforcing our market-leading capabilities. Second, we doubled down on our mobile research to ensure our unlocked capabilities continue to keep pace with the major phone manufacturers. We believe these investments will extend our leadership in Android and will reassert our leadership in iOS. We expect this range of leadership capabilities will hit the market over the coming six weeks and position Cellebrite as both the leader across each major segment as well as the clear leader from a comprehensive cross-platform perspective. Third, SaaS and cloud adoption remains outstanding.

ARR for these offerings grew north of 50% and now represents 22% of total ARR. Guardian’s impressive trajectory continued with its now sixth straight quarter of 100%+ year-on-year growth. Guardian Forensics is rapidly becoming the industry’s de facto repository for evidence that matters and where chain of custody is critical. Fourth, we completed our acquisition of Corellium in early December while we continued our work to gain final clearance from CFIUS. Corellium’s ARM virtualization technology remains an industry-unique and powerful asset. Customer interests across both defense and intelligence and the private sector continue to exceed expectations. We remain confident this asset will be highly accretive to our growth and will exceed our pro forma expectations when we announce the transaction in June of last year.

Looking ahead to 2026, we start the year well-positioned to reaccelerate growth with initial guidance of 18%-19% as compared with our organic growth of 17% in 2025. We see several levers for further acceleration as our portfolio and solutions evolve over the coming quarters, but chose to take a prudent approach to our guidance until these assets become generally available and we can confirm expected market adoption. Let me recap the primary contributors to our expected reacceleration. First, core demand for our solutions remains strong. Macro tailwinds around crime, population growth, the use of digital in both the pursuit and resolution of crime continues to climb as validated in our recently released industry survey, and the constraints associated with human capital persist. Unfortunately, these known established macros have been exacerbated the past year by increased geopolitical tensions around the world.

Second, the well-chronicled disruptions in the U.S. federal segment are thankfully now behind us. Excuse me. We expect the roughly flat growth performance of this unit in 2025 to reaccelerate and to exceed the company’s overall growth rate in 2026. There are multiple drivers that will contribute to this resurgence in growth: pent-up demand and core unit growth, increased and focused federal funding, and the final DOJ-sponsored authorization to operate for FedRAMP Level 4, which we expect to obtain before the end of this quarter after a lengthy 18+-month process. Federal ATO will pave the way for Guardian and our cloud assets in the U.S. federal market. Augmenting these growth engines is our increased focus on more targeted defense and intelligence solutions as well as the product fit of Corellium and DNI.

Given current mid-quarter visibility, we’re optimistic this unit will get off to a fast start in the first quarter. Third, we’ve elevated the quantity and quality of our go-to-market organization with a roughly 20% expansion in sales executives and our increased investments in enablement and training. Fourth, within digital forensics, there are several important levers. In terms of Inseyets conversions, the value proposition of our Inseyets upgrade cycle is now well understood, and many agencies have incorporated their upgrades in their planning and budgeting cycles for 2026. These dynamics position us well to drive conversions this year by an additional 25%+. Just as important, based on our anticipated platform leadership, we expect accelerated growth in the unlocked business as we enter the second quarter and the remainder of 2026. Fifth, we took an important and exciting step today with the agreement to purchase SCG Canada.

The deployment of drones globally is not just growing. It’s exploding. The drone market is expected to grow 20%+ annually and surpass $53 billion by the end of 2026. Its constructive use cases are broad, ranging from surveillance and commerce to the safety of local law enforcement and national defense. Unfortunately, drones also enable nefarious use cases. The U.S. alone reported over 1.2 million drone violations in 2025. We believe drone forensics will rapidly become one of the most significant data sources for making our nation’s communities and businesses safer. Given our leadership in digital forensics and our customers’ trust and dependence on our digital insights, adding drone forensic leadership was both a logical and candidly necessary strategic decision.

This is a capability that will bring immediate value to defense intelligence and law enforcement agencies as well as to the private sector that’s charged with securing airspace around critical infrastructure, prisons, and dense locations such as airports and sports venues. This represents a modest but important move to address an emerging need and further elevate the impact of our AI-powered platform for multi-data source analysis. We expect to close this transaction by the end of the first quarter, and we’ll share additional details upon closing. Sixth, with the recent closure of Corellium, we enter this year transitioned from a reseller to a fully integrated selling motion. We’re driving elevated education and training across the Cellebrite go-to-market team and customer base and see meaningful growth opportunity across both the public and private sectors. Corellium will also clearly exceed the company’s overall growth rates.

We’re excited and optimistic about our progress in emerging leadership in digital investigations and analytics. These strategic assets grew 2.5 times faster than the overall business in 2025. Guardian Collaborate and Guardian Forensics are well-positioned to sustain their 100%+ year-over-year growth rates. In addition to the important ATO for the U.S. federal market, we expect to obtain similar certifications in Australia, New Zealand, and select European nations later this year. We will also launch Guardian Investigate this spring.

This product is squarely focused on enabling criminal investigators, detectives, analysts, and prosecutors to build stronger case narratives, collaborate seamlessly in a secure workspace, leverage a diverse set of data sources and file types, including traditional smartphones, but also adding important sources such as call detail records, open-source intelligence, video, RMS, ballistics, and license plate data, and ultimately leveraging the most powerful AI-enabled analytics in the industry to navigate and interrogate this mountain of important evidence. Feedback from beta and customer design partners has been exceptional, and we think is a harbinger for accelerated deployment and growth in the second half of 2026. Pathfinder, our flagship analytic solution for multi-phone forensics, continues to grow and deliver important levels of insight and productivity to a growing percentage of our Inseyets install base. And last, but certainly not least, is our progress in the thoughtful and ethical use of Gen AI.

We’ve been pioneers in the use of machine learning and AI for the past decade and plan to extend that leadership in 2026. While many view AI as a threat to software, we view AI as an absolute tailwind across three fronts. The first is applying it across our internal organization to drive productivity and efficiency, and this initiative is well underway. Second, AI enables significant improvements to the productivity of users of the Cellebrite portfolio, which ultimately elevates our value proposition and customer retention. And third, we see meaningful opportunity to monetize unique and focused Agentic applications that bring rich capabilities that transcend a range of use cases from child exploitation and missing children to cybercrime to stagnant cold cases and major criminal investigations.

I want to briefly expound on our constructive view on AI and why we view it as a force multiplier from both a business and a societal impact. Cellebrite’s mobile extractions are at the epicenter of the most valuable, complex, and difficult-to-obtain sources of evidence that are relevant to virtually every investigation and the corresponding power and capabilities of any AI engine. Said more simply, our unique intimacy with the most complex evidential artifacts gives us a unique advantage in harnessing AI for good. That intimacy is then compounded by our domain expertise with investigative workflows leveraged by hundreds of man-years of law enforcement experience. Finally, Cellebrite’s history is grounded in the quality, ethics, compliance, and security that’s earned us the trust of thousands of the largest and most sophisticated public safety and government agencies around the world.

Gen AI can and will be a powerful force for good, but the stakes involved in crime and sovereign defense demand that advanced analytics are complemented by full traceability, ethical use, and human verification. To conclude, I’m proud of our progress in 2025. We navigated turbulence in the U.S. federal space while still delivering healthy growth in both the top and bottom line. Just as important, we made critical investments throughout 2025 that span organic innovation, strategic partnerships, and targeted acquisitions. Leadership and innovation matter, and we continue to invest in the long-term growth and leadership of this company. We enter 2026 with a truly differentiated end-to-end AI-powered platform that delivers high-value insights and intelligence from an expanding range of data sources. We are already hard at work on where and how we can expand our value for 2027 and beyond.

We have a bold aspiration to not just solve crime with efficiency but to ultimately drive a material reduction in crime itself. We’re proud of our impact in the world, and we’re anxious for the future. With that, I’ll turn the call over to Dave. He’ll do a walkdown on the details and add further insight to our first quarter and full-year guide. Dave?

Andrew Kramer, Investor Relations, Cellebrite: Thank you, Tom. I’d like to briefly share highlights from the fourth quarter and full year. ARR grew 21% to $481 million, which includes Corellium. When we closed the acquisition on December 1st, Corellium’s ARR was $16.1 million. Excluding this, our ARR grew 17% year-over-year, and sequentially, ARR increased 6% over Q3. Perhaps even more noteworthy, after experiencing headwinds in the first three quarters, our net new ARR growth in Q4 was back to prior year levels. This aligns with the remarks and the confidence we shared on our last earnings call that growth would reaccelerate in FY 2026. Geographically, the Americas represented 53% of total ARR, while EMEA represented 35%, and Asia-Pacific represented 12%. In terms of growth rates by geography, the Americas grew 19%, with our U.S. state and local government and Latin America teams leading the way. EMEA grew 24%, and Asia-Pacific increased 23%.

Higher growth solutions like Pathfinder, Guardian, and now Corellium have become a larger percentage of our ARR mix. At the end of 2025, these solutions represented 14% of total ARR, and we anticipate that this mix will continue to shift closer to 20% by the end of the coming year. Turning to revenue, in our Q4, revenue grew 18% to $128.8 million, which includes approximately $1 million from the Corellium acquisition. For the full year, revenue grew 19% to $475.7 million. Our software solutions drove approximately 90% of our fourth quarter and full-year total revenue. Our fourth quarter gross profit increased to $110.8 million, which represents a gross margin of 86%. Our full-year gross margin was 85%. Fourth quarter Adjusted EBITDA of $38.3 million increased 33% over the prior year, and the margin expanded by 340 basis points to 29.8%.

For the full year, we generated Adjusted EBITDA of $127.6 million, or 26.8% on a margin basis. We achieved this level of profitability despite a strong FX headwind as the shekel strengthened materially against the U.S. dollar. As Tom noted, we have continued to balance the investments required to drive innovation and fuel expansion with our focus on giving our teams the AI-enabled tools to elevate productivity and efficiency. We ended 2025 with 1,285 employees, up 10% over 2024. Turning to the balance sheet, we ended 2025 with $535 million in cash, cash equivalents, and investments, up $52 million despite the outflow of $147 million in net cash used to acquire Corellium in December. Free cash flow for the fourth quarter was $82.3 million. For the full year, free cash flow was $160 million, or 34% on a margin basis.

This represents 30% growth over 2024 Free Cash Flow of $124 million or a 31% margin. As a reminder, we remain very focused on reaccelerating ARR growth while maintaining a Free Cash Flow margin of at least 30%. As a vertical software company we believe will be a beneficiary of AI, we are of the view that a strong ARR growth combined with a strong Free Cash Flow margin strikes the right balance and enables us to serve all stakeholders. Let’s shift gears and take a look at our 2026 expectations. Before I review our guidance, I wanted to share a few thoughts around our guidance philosophy in response to investor questions on this topic. While we were very deliberate about not changing Cellebrite’s guidance framework when I joined the company midway through 2025, we have modified our guidance philosophy for 2026.

In particular, we focused on setting prudent ARR and revenue expectations around tighter ranges that are corroborated by our renewals deal pipeline and applicable RPO coverage. Accordingly, we’ll use tighter ranges for our quarterly and annual ARR and revenue targets. As we execute over the coming quarters, we’ll reassess and revise those top-line targets as appropriate, and the same is true for Adjusted EBITDA. Our initial view into 2026 ARR calls for a reacceleration in our growth rate versus the 17% organic expansion we delivered in 2025. I’d like to quickly revisit the framework from November on the 2026 drivers. First, winning new logos and increasing price or mix on existing offerings is expected to generate several percentage points of growth. Second, Inseyets through conversions, more pervasive deployments, and upsells on unlocks is anticipated to support growth in a meaningful way.

Our third growth driver involves Guardian and Pathfinder, the cornerstones of our digital investigation and analytics offerings. We expect this will contribute mid-single-digit percentage points to our ARR growth. Corellium, our fourth driver, continues to experience healthy customer interest and demand. While it is still early days, we expect a contribution of at least a couple of percentage points to growth. And finally, we expect to improve gross retention. In terms of our planned acquisition of SCG Canada, we have not yet incorporated any contribution into our outlook since the deal has not yet closed. It is worth noting that while SCG is currently a small business, it will bring innovative technology that we believe is highly complementary to our platform and will benefit greatly from our global distribution.

Looking at the first quarter, we expect ARR growth in the range of $491-$493 million, or 20%-21% growth. The combination of our recent Q4 ARR and our anticipated Q1 ARR demonstrates not only sequential stability but an expansion motion in terms of absolute dollars versus the comparable quarters one year ago. We expect first-quarter revenue in the range of $127-$129 million and an increase of 18%-20%, and Adjusted EBITDA in the range of $26-$28 million with a margin of 21%-22%.

For full fiscal year 2026, we expect ARR in the range of $567-$573 million, or 18%-19% growth, revenue in the range of $565-$571 million, or growth in the range of 19%-20%, and Adjusted EBITDA in the range of $149-$155 million with a margin of 26%-27%. As Tom noted, we are in the early stages of evolving our products and packaging in ways that are intended to ultimately make it easier for customers to expand the range of solutions they subscribe to over a multi-year period as they take advantage of our cloud and AI-enabled offerings. While we anticipate this will serve as a stronger foundation for durable ARR growth, we also expect that a byproduct of this transition will be more radical revenue recognition over time.

As a result, we continue to view ARR as the most relevant top-line KPI. As you consider our outlook for profitability, I’d like to highlight a few elements. We anticipate, in line with prior fiscal years, approximately 60% of our Adjusted EBITDA dollars will be generated during the second half of the year, which will be accompanied by stronger Adjusted EBITDA margins. Our profitability also reflects two transitory headwinds that weigh on margins. The first item reflects the absorption of incremental Corellium costs we’ve added following the acquisition. We expect this impact will dissipate by the end of this year as top-line expands. The other factor is foreign exchange, most notably the continued strengthening of the shekel against the U.S. dollar. We continue to thoughtfully manage our overall cost structure while also taking pragmatic steps to limit the impact of FX volatility.

In terms of Free Cash Flow, we’re expecting 2026 to be another strong year with anticipated FCF margins in excess of 30%. Finally, I’d like to offer a thought on Cellebrite’s Rule of X performance. Historically, we have calculated our Rule of X by adding our ARR growth rate and our Adjusted EBITDA margin. As we have scaled our business and matured our execution, we have delivered Adjusted EBITDA margins at levels well above the original floor of 20%. Accordingly, we now view 25% Adjusted EBITDA as our new floor on profitability, which also correlates at a high level with a Free Cash Flow margin of at least 30%. Since more radical revenue will impact both top-line and bottom-line rates of expansion, we will be using ARR growth and FCF margin to measure our Rule of X. We feel this will provide investors with more clarity and insight.

Building on Tom’s comments around Rule of X, we begin the year with an outlook in the upper 40s and an objective to drive performance to 50+. Overall, the team delivered a successful 2025 despite the transitory headwinds in the U.S. federal market. We are moving into 2026 with optimism around our prospects to further reaccelerate ARR growth while delivering attractive profitability and Free Cash Flow. We look forward to sharing our progress in 2026 with you as we execute on our plans over the coming quarters. Operator, that concludes our prepared remarks. We are ready for Q&A.

Tom Hogan, CEO, Cellebrite: Thank you. The floor is now open for questions. At this time, if you have a question or comment, please press star 1 on your telephone keypad. If at any point your question is answered, you may remove yourself from the queue by pressing star 2. Again, we ask that you pick up your handset when posing your questions to provide optimal sound quality. Thank you. Our first question is coming from Bobin Shaw with Deutsche Bank. Your line is open. Please go ahead.

Speaker 1: Great. Thanks for taking my questions and congrats on solid into the year and a strong 2026 guide. Maybe first on the acquisitions. I mean, you kind of announced SCG Canada. You’re expected to close kind of 2 deals in quick succession. How are you guys thinking about ensuring that you can execute against the strategy for both of these deals along with maintaining a focus on the core? Do you feel like you have to make any internal changes as you fold these companies in? And how are you guys thinking about allocating resources amongst the core relative to Corellium and SCG?

Tom Hogan, CEO, Cellebrite: Thanks, Tom. I’ll take it. So first, the Corellium transaction took longer to close than we anticipated. The good news with that is we’ve now had essentially 7+ months since we announced the deal to get into a rhythm and a cadence. We inked the reseller deal quickly after announcement given some of the delays. And so from a training, go-to-market, there were limitations, obviously, that you have where you can’t fully operate as one entity pre-close. But while it may feel concurrent given that that closed early December and we expect to close SCG by the end of this quarter, realistically, or from a sort of an executional challenge perspective, there was pretty good spacing between the two. And then the second thing, and I’ll probably anticipate the question that somebody’s going to ask is, how big is the breadbasket with the SCG deal?

We’re super excited about it because just the drone world is, as I said, exploding, and having market-leading drone forensic capability is hugely compelling. And so we think the growth trajectory of that business is also going to be I’ll just say, and I hate to use exaggerated terminology, but breathtaking, I think, description. But for our stakeholder, it’s currently a small operation. So they’re the market leader in our view, but we’re talking about a business that’s low single-digit millions. And so the complexity of that business and by the way, this is what we do. So instead of using our devices on UFEDs to extract forensic data from phones, we’re now using their CFID to extract forensics from a drone. And so this couldn’t be more sort of core and complementary to who we are and what we do.

The due diligence here is actually relative to a standard acquisition. The due diligence here is low.

Speaker 1: That’s super helpful there. Just a quick follow-up just on the last point you were talking about, the drone opportunity, understanding it’s still very nascent here, but how did this kind of come about in terms of looking at the asset? Was this something that customers were asking for, or is this something that, look, as you look 2-3 years, 5 years down the pipe, this is something that’s going to be more meaningful? What drove it, and how did you know what budgets are coming from as well?

Tom Hogan, CEO, Cellebrite: Yeah. So the good news is the answer is both. So in particular, in the short run and Marcus might comment on this, but in the defense and intelligence world, they’re already using the technology. And as they look to their plans and procurement and the need to expand given the proliferation of drones, the demand from our mutual customers is loud and clear.

And then as we do strategic planning, one of the things you would expect from us is to always look out, kind of skate to where the puck’s going from a TAM perspective, and say, "What are adjacent markets that bring big TAM to the Cellebrite value proposition?" And the moves we’re making in the whole investigative world and analytics, now combined with the moves we’re starting to make in drones, the TAM of those two added markets is actually about 5x the core TAM that we’ve been chasing for the last 19 years. So both from a strategic planning and customer demand, it was sort of one of the most obvious strategic moves I’ve seen in my 43 years.

Thank you.

Marcus Jewell, CRO, Cellebrite: Yeah. I’ll add, sorry. I’ll just add to Tom’s comment there as well that yes, there is customer demand. Where we’re deploying, we effectively take data from sensors. The biggest sensor out there is a cell phone. But a drone in full deployed in borders and those areas is one of the other sensors, which is definitely required. So yes, there is already demand, and there’s already trading for those solutions.

Tom Hogan, CEO, Cellebrite: Thank you. Our next question comes from Jonathan Ho with William Blair. Please go ahead.

Speaker 5: Hi. Good morning. Let me echo my congratulations as well. I wanted to start out with maybe a little bit more color on the investments that you made to extend your mobile forensics leadership that we’ll see later on this quarter. Could you maybe help us understand what this could mean from either improving net retention, win rates, or product expansion perspective?

Tom Hogan, CEO, Cellebrite: Yeah. So Jonathan, the investments were basically doubling down with our internal research team to both extend our leadership in Android and to also ensure that look, we would love for people to just standardize on us for the front-end unlock and access from a platform perspective, but we don’t want them to feel like they’re making any sacrifice. So the goal is to have a leadership offering in both of the major OSes, both Android and iOS. And so the investments were made in our internal research team to make that happen in conjunction with several external partnerships, which, by the way, is not new. It’s sort of standard operating procedure for us for the last 15+ years to leverage the combination of our internal badged researchers with some of the best and brightest researchers in the world to help complement our capabilities.

We’ve doubled down on one of those partnerships, and we’ve added another one that helps bring new attack vectors for exploits and vulnerabilities. When you roll those partnerships together with the innovation, that’s why we feel so optimistic about us having a very clear leadership position across the board. If that comes to fruition, given the importance of access, it will clearly drive accelerated growth on the front end of our unlock access and our Inseyets penetration and market share and year-to-year growth.

Speaker 5: Got it. And then just in terms of your comments around the U.S. federal government spending environment, where are you seeing maybe the most pent-up demand? Where are you seeing sort of improvement in terms of sort of the malaise that we saw last year? And what sort of gives you the confidence that this can sort of return to a stronger growth rate? Thank you.

Tom Hogan, CEO, Cellebrite: Yeah. I covered the macro categories, but I’ll let Marcus because he’s really dialed in and close to this. He can give you maybe a better answer, but I think you’ll hear there’s sort of empirical data and meat behind our enthusiasm. But Marcus, why don’t you take a shot at that question?

Marcus Jewell, CRO, Cellebrite: Yeah. It’s kind of a doozy, as we said, over the last six months. So what we’re seeing is reminding everybody of the use cases which are used. There’s obviously the defense and intelligence use cases, which the world continues to get stranger and stranger and more threat. So in four deployment areas where data collection in the new kind of war situation is incredibly important, we’re seeing those use cases build out and a lot of confidence build around those, not only on a federal level but also on a global national level. You saw that strength in our EMEA results as well. Border security continues to be, across the world, a big area, and a lot of money is going into that. Then there’s also some external things. There’s a big World Cup, FIFA World Cup, coming to the U.S.

That’s going to be potential for a lot of serious crime, and that has to be prevented as much as possible. We are used in the deployment of those areas. That’s the confidence that we see. The agencies, remember, under the big beautiful bill, were given a two-year budget. They’re able to get ahead now and start thinking and plan more strategically. Our competitiveness with our product means that we’ll feel comfortable in those positions. It’s the same story of those hardening use cases with more stability from that. Then the final point, as Tom mentioned in opening remarks, will be the ATO, the Authority to Operate, for our Guardian solution, which means we are unique in a position of the only people that can actually store and share forensic data under the FedRAMP approval.

That opens up multiple petabytes of opportunity for us to capitalize once we get through the ATO process in the next few weeks.

Speaker 5: Thank you.

Tom Hogan, CEO, Cellebrite: Thank you. Our next question comes from Shaul Eyal with TD Cowen. Your line is open. Please go ahead.

Speaker 9: Thank you. Good afternoon, everybody. Congrats on solid 2025 completion. Tom, maybe just for clarification, I’ve been getting some emails from investors. On that small drone tuck-in acquisition, the scope, the $1 million-$9 million, I think you’ve indicated, is that the price paid, or is that potentially ARR contribution? I don’t know, first half or maybe even first quarter once you close it. And maybe any headcount number you can provide us with as it relates to this acquisition. And I have a follow-up.

Tom Hogan, CEO, Cellebrite: Yeah. Yeah. Okay. Good question. So let me be clear and helpful. So we’re inheriting a low single-digit ARR run rate. It’s a small-scale, although market-leading solution. Price paid, we haven’t closed yet, so there’s a couple of conditions that we’re chasing down here in the next week or two, but we’ll be in the $15 million-$20 million range for the company. And then we’ll be disappointed in the midterm if the ARR growth potential for that business isn’t well north of that $15 million-$20 million. So we’re hitting this at the right time, which part of what we moved fast here, and we think asserting ourselves as a first mover at scale to address drone forensics is going to pay big dividends for the company.

Speaker 9: No question about it. Makes a lot of sense. Maybe with respect to the model, how should we be thinking about second half versus first half linearity? Should it mostly resemble 2025 trends, or should there be any maybe kind of little deviations as we think about second half versus first half?

David Barter, CFO, Cellebrite: Great question. Thank you for asking it. I would actually model it from a top-line perspective, model it pretty close to 2024 in terms of that split, which was largely a little less than 40 in the first half and 60 in the second half. That kind of maps to what I think Tom highlighted in his remarks around the number of offers that are coming to market.

Speaker 9: Thank you so much. Good luck.

David Barter, CFO, Cellebrite: Thank you so much.

Tom Hogan, CEO, Cellebrite: Thank you. Our next question comes from Jeff Van Rhee with Craig-Hallum Capital Group. Your line is open. Please go ahead.

Speaker 4: Great. Thanks. Thanks for taking the questions. Congrats on that free cash flow margin in particular. Tom, on the AI side, just spend a second and talk a bit more about these opportunities. Specifically, you talked about agentic applications, cybercrime, child exploitation, etc. Just talk a bit more about exactly what those would be and how you monetize them, if you would?

Tom Hogan, CEO, Cellebrite: Yeah. So we’re parallel kind of tracking our efforts in AI. So there’s a lot of work being done by the core product and technology team to integrate advanced AI capabilities that drive productivity. So think things like media classification and summarizing text chats and report generation and identifying conflicts in testimony and just a list of things that turbocharge our current stack and deliver a lot of productivity to our users. And we’re going to continue to elevate and identify more opportunities to do that real-time. In parallel, we have an AI innovation center that’s been missioned with developing more specific agentic applications and use cases that, based on feedback from design partners and some sort of early evaluators, I guess, are getting. We’re kind of pleasantly shocked at people’s enthusiasm to begin to deploy these agentic apps.

I gave you some examples, and I won’t name the departments, but in talking to the chief of the investigative unit in the large U.S. police department, his response was, "So wait a minute.

I can deploy this app and just turn the engine loose on a stack of missing children cold cases and see what this application can surface that might provide added insights that we had overlooked and then merit or make it worth the time of a detective to circle back and pursue the investigation." So in terms of your question, Jeff, about monetizing, the candid answer is we are working on that real-time as we speak to figure out and I think a lot of software companies are sort of wrestling with what do you sort of bundle as an enhancement and a value add to the product’s core capability, which we’re doing with Guardian Investigate, and then what are the things that you can monetize, and then what are the price points?

One of the messages I would give to the shareholder base is, candidly, the guidance that we have in place today assumes the assumption and the guidance assumes that we don’t monetize any of that in 2026. And based on the feedback we’re getting, I actually think there is going to be an opportunity in fiscal and calendar 2026 to start to monetize some of these agentic applications.

Speaker 4: Yeah. Great. Fantastic. A couple maybe from Marcus. Just Marcus, it looks like. I think maybe Tom called it out in the script, spending or adding 20% more capacity in terms of sales heads. Talk about just where you’re allocating those heads. How are you thinking about the assignment and where you’re pointing those folks? And then in particular, if you comment on DNI, obviously, with SCG and Corellium, you seem to have a deeper toehold. And TAM opportunity in DNI, does that require a different motion, different touchpoints, and is that an area of particular focus?

Marcus Jewell, CRO, Cellebrite: Indeed. Yeah. Let me break that down. So we’ll start with public safety, which is the largest part of the business, as you know. There’s still scope to add heads there. We feel that our coverage, even in SLG in the U.S., can increase. And so we’ve increased in penetration, especially into the medium and small agencies across the U.S. So that’s one area where we’ve put a well-trodden motion, and we repeat and extend on that. The next area, which is probably getting missed, is through the Corellium play. We have a VIPER, which is a pen-testing solution, which is proving very, very interesting and successful with the enterprise. So we’ve increased our coverage in the enterprise business for our mobile app penetration testing. Actually, Financial Services is one of the largest customers we have.

A lot of you guys on the banks there run multiple apps, and they need to be checked that they’re safe and cannot be penetrated. That’s been a real uptick for us. We’ve increased our coverage on the specialization there. The third area is DNI, and we’re delighted that we’ve brought back one of our leading salespeople who left us for a little break and has come back to head up a global development there. He’s an ex-special forces person, and he’s driving a new global standard for us around the DNI space. We’ve added resources both in Europe and the U.S. to cover that.

Speaker 4: Wow. Maybe just one last for me then, Marcus. On the FedRAMP, is there a backlog sitting there that had been kind of waiting for this, and should you see a surge from that? And then maybe to put a finer point on it, I think in the prior call, you or Tom, I believe, had mentioned a very large deal. I believe you’d said the largest deal that you’d ever seen. That was looking like it was lined up for an H-126 close. If I have that right, can you give any update on that?

Marcus Jewell, CRO, Cellebrite: Yeah. So let me tackle the second part of the question first. So we have multiple threads of large annual spend in the first and second half of this year. So we feel confident about our position trending there, but I’d like you to think about that. There’s not one single customer. There’s actually three or four different programs, which are all in seven figures for us. So we continue to track well, and we feel good about our technical evaluation position in multiple threads there. The second point is could you actually ask the first question again? Sorry. I lost my thread there.

Speaker 4: I think we were talking about the federal side. I was most interested in the big deal that you had talked about.

Marcus Jewell, CRO, Cellebrite: Yeah. The big deal continues to track well. So we feel good about that. These big deals tend to scale up and grow. Procurement can be complicated, but we feel good. But I want you to think that there’s not one. There’s multiple agencies, both in state and local and in federal, which have multiple big deal opportunities for us. So we continue to track well against the one we highlighted, but we’re actually adding fuel to the fire on that. And then the first part, sorry, was ATO has come back to me now. Yeah. Look, I mean, when you say backlog, I’ve got to be careful because a backlog would suggest that we have a purchase order. What we do have is we’ve seen our largest bid go out. We have scoped an initial contract for a large federal agency and their storage requirements, which exceeds 9 PB.

That would equate to a very large deal. That would be certainly the single biggest transaction we would have ever done. We continue to track well. We want to get through the ATO process, which we’re confident on, and then we will talk about turning that into real revenue as quickly as we possibly can.

Tom Hogan, CEO, Cellebrite: Thank you. Our next question is coming from Mike Cikos with Needham. Your line is open. Please go ahead.

Speaker 7: Great. Thanks for taking the questions here, guys. And I’ll echo the congratulations on the strong finish to the year. I wanted to come back to the insights conversions and the unlocks for a second. Can you help us think about how the adoption of unlocks trended in Q4? And Dave, I know you went through a number of different vectors that give you guys confidence in that ARR reacceleration in the coming year, but what are your assumptions as far as how insights and unlocks play into that? I just want to make sure I was clear on that, and then have a follow-up.

David Barter, CFO, Cellebrite: Okay. Mike, let me kind of break them apart between the insights and the unlock because I think they’ll have different dimensions. I think we ended it with insights at about 55%. Overall, I think we feel good. I think that will follow our overall broader deal seasonality just from the standpoint that the transitions will probably occur with contract expirations, and so probably follows that linearity of or the seasonality I described earlier bound how things unfolded over the course of fiscal year 2024. The unlocks will be a little bit different just from the standpoint that, as Tom alluded to, there is work and new technology that’ll be hitting the market. And so that really will start to kick in in what I’ll call late Q1, but really Q2, and then I think it builds and it ramps from there.

Now, some of it will be linked to expiring agreements. Some of it will be expansions of existing deals. And that’s a little why we called out in his remarks. We want to see how the market reacts to give you a little bit more color around how it unfolds. So we have, I guess, Mike, I have a thesis, but I need a little bit more data, and that was kind of incorporated in the guidance.

Speaker 4: Understood. Okay. Thank you for that. And then for the follow-up here, just wanted to get a better understanding. I’m happy that we have Corellium in the rearview as far as the closing in December and then the expectations for a couple of percentage points growth in the coming year. Can you just help us think about the cost base that Cellebrite is now carrying for that asset and how that impacts the calendar 2026 guide? I know you cited specifically Corellium as well as the headwind from an expense perspective tied to FX, but just wanted to make sure I was thinking through that properly.

Speaker 7: Yeah. So let me maybe just kind of tether it with some numbers. I mean, it’s about a point of compression on margins due to Corellium, and I think, as we shared in the remarks, we’ll grow into it over the course of the year. So it’s a little bit heavier in the first couple of quarters. We’ll get some leverage in the second half, and as we go into 2027, we’ll be cooking well. And so we kind of picked up a wonderful, wonderful technical team, and we’re really excited with what they’re already doing. And then FX is a headwind; it’s more than a point that’s ultimately burdening the P&L. We ended the year with a pretty healthy hedge, but nonetheless, we’re taking on a healthy point of compression just due to the strength of the shekel.

So about two points of extra headwind than what we expected, and I think it ends up being a temporary headwind in the sense that I think it actually passes through the P&L this year, and we kind of come out the other side with better profitability. And again, I think cash flow margins continue to remain at a pretty compelling place. Does that help, Mike?

Tom Hogan, CEO, Cellebrite: Thank you. Our next question comes from Brian Essex with J.P. Morgan. Your line is open. Please go ahead.

Speaker 7: Great. Thank you for taking the question, and congrats on the results. Great to see the stabilization, particularly in the Fed. Maybe, Dave, if I could maybe have you unpack a little bit of the commentary you had on the guidance, particularly with regard to the prudence of guidance and the tighter ranges around ARR for your targets, could you maybe help us understand the philosophy that the company had over the past few years and maybe how that’s changed, how it’s tighter? Where are you narrowing the guardrails? Is it around upside to give yourself more cushion, or maybe just help us understand the level of conservatism and the setup as we kind of head into fiscal 2026?

David Barter, CFO, Cellebrite: Okay. It’s a great question. Thank you. I think if you were to rewind the clock and compare where we are today versus where we were, I think we had a $15 million spread on ARR last year. Right now, we’re calling a $6 million spread. And I think what you’ve probably, Brian, you’ve seen is I think there’s a pretty healthy degree of forecast accuracy. And so we’ve rolled through, and quite frankly, as you know, the business has a strong customer base motion, and it’s complemented by a smaller new logo motion just given how the initial lands happened. So we really used our customer base motion to really inform it. And so we actually looked at the pattern of our expirations, looked at the upsell. This is where we went from the expirations to the expansion at the time of renewal.

That’s what we started to model in. Then we built in some of those points that Tom talked about, but where we had a little bit less feasibility, that’s where we snapped the chalk line. So that’s how we kind of ultimately got to a $6 million spread, looking at the 2018 to 2019, and then we pulled it through the P&L.

Speaker 7: Maybe that variability was previously included in the guide, and maybe you’re pulling that back a little bit?

David Barter, CFO, Cellebrite: Correct. I mean, in general, I kind of look out, and as I look at it, I try to go for a high degree of visibility. And then as I get a little bit smarter, ultimately, that’s what I incorporate. And so it’s a little bit as you’ve kind of looked at, okay. Super.

Speaker 7: Oh, yeah. Sorry. Then maybe just to follow up on your comment around gross retention, the comment that you expect to improve gross retention, where have you seen maybe the points of improvements, and how does that translate into what you have for expectations into fiscal 2026?

David Barter, CFO, Cellebrite: Yeah. It’s a great question. I guess I start to see it almost beginning with kind of our flagship or our platform in the form of Inseyets and unlock. And so I think there are signs that that’s going to get better. And then, quite frankly, with the maturity of where we’re at, both on Pathfinder and Guardian, I think we see the signs whereas we have customers really operating on very current versions of Pathfinder and expanding on those versions, and then certainly, quite frankly, just the build-out on the Guardian platform. So there’s a number of compelling features. And then, as Tom alluded to, the customers that are starting to experiment, these are our design customers using AI that naturally ties into both Guardian and Pathfinder. And so they will get, quite frankly, pronounced impact from the adoption of AI.

The fact that they’re uploading more and more data and using it that way, I think, gives us increased conviction.

Speaker 7: Got it. Very helpful. Thank you so much.

David Barter, CFO, Cellebrite: Great questions. Thank you.

Tom Hogan, CEO, Cellebrite: Thank you. Our next question comes from Eric Martinuzzi with Lake Street. Please go ahead.

Speaker 3: Yeah. Tom, I wanted to dive a layer deeper on your comments regarding AI. Curious to know, in your conversations with customers, obviously, there’s tools that they use outside of your C2C platform. Are they pulling you in a direction as far as where they want you to see enhancements made in the platform, or is it just, "Hey, we’ve got AI within the C2C platform, and people aren’t straying from that?

Marcus Jewell, CRO, Cellebrite: Can you try that again? I’m not sure. Ask again to just make sure I answer the.

Speaker 3: Yeah. There are kind of open-market tools for generative AI outside of the C2C platform. Just curious if customers are pulling you in a direction where they want to see investments made in your platform, tools they’re using that aren’t selling.

Marcus Jewell, CRO, Cellebrite: Yeah. Got it. Okay. No. Yeah. Nope. The good news is everybody’s tinkering. And what the early tinkerers are discovering, especially as they start to see and hear about what we’re doing, candidly, they’re seeing a huge gap in what we’re able to produce in terms of the depth, the quality of kind of the AI output, which makes sense for the reasons I shared earlier, given our knowledge and access to the complex and critical phone data. And so instead of them saying the honest answer right now is instead of them saying, "Hey, can you kind of shift course 10 degrees here because this is what would help me," or, "This is where I’m going," as they’re learning and discovering what we’re doing, actually, what they’re saying is, "I’m going to stop, and I’m going to adopt the products and the capabilities that you’re bringing to market.

Speaker 3: Understood. And then, is that as you look at the pipeline and this is kind of product development pipeline. You talked about forensics investment as a key area. How are you using AI in that forensics investment part of the R&D?

Marcus Jewell, CRO, Cellebrite: Are we using?

Speaker 3: You want to maintain your leadership.

Marcus Jewell, CRO, Cellebrite: Oh, wait.

Speaker 3: Sorry. You want to maintain your.

Marcus Jewell, CRO, Cellebrite: Are we using AI for leadership?

Speaker 3: Right. Specifically in the forensics part of the product.

Marcus Jewell, CRO, Cellebrite: Yes. So if your question is, "Are we leveraging AI to extend or maintain the forensic capability?" Is that the question?

Speaker 3: Yes.

Marcus Jewell, CRO, Cellebrite: To be honest, what we’re leveraging more right now from a technology perspective is the Corellium asset. So that’s been a tool for us for the past five years, and now we own it. So we use that to accelerate the identification of vulnerabilities and exploits. If the question is, "Is there a magic AI engine that can go surface vulnerabilities?" maybe that will happen in three years or five years, but we don’t see that right now.

Speaker 3: Yeah. Just obviously, all software stocks, and yours in particular, seem to have gotten hit here the past few weeks. With that assumption in mind, it’s a head-scratcher for me. I’m sure it is for you guys as well, but just had to ask the question.

Marcus Jewell, CRO, Cellebrite: Yeah. No. I think what we would say generally is, given the nuance of what we do, the specific use cases, the workflows, the complexity of the data on phones, this is not some standard research or task that a lot of these engines are capable of essentially outsourcing and driving. And so this is why we think AI for Cellebrite and probably a handful of other companies in very specific nuanced industries is actually a tailwind and a force multiplier for us that we’re going to harness and both deliver value to our shareholders but also deliver more value and speed and insight to our customers.

Speaker 3: Got it. Thanks for taking my question.

Marcus Jewell, CRO, Cellebrite: Yeah. We scratch our heads on the whole AI is going to make software go away. We have kind of the complete opposite view, so.

Tom Hogan, CEO, Cellebrite: Thank you.

Speaker 3: Operator, any other questions?

Tom Hogan, CEO, Cellebrite: This does conclude the Q&A portion of today’s call. I would now like to turn the floor over to Andrew Kramer for additional or closing remarks.

Andrew Kramer, Investor Relations, Cellebrite: Thank you, Operator. I’d like to thank everybody for joining us this morning. If you do have any questions, please feel free to follow up with Investor Relations, and we look forward to speaking with our shareholders and prospective shareholders over the coming days and weeks. Thank you.

Tom Hogan, CEO, Cellebrite: Thank you. This concludes today’s Cellebrite fourth-quarter and full-year 2025 financial results conference call. Please disconnect your line at this time and have a wonderful day.